INFED PRESCRIBING INFORMATION PDF

INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.

Author: Mebei Faekus
Country: Liechtenstein
Language: English (Spanish)
Genre: Marketing
Published (Last): 23 November 2016
Pages: 13
PDF File Size: 12.80 Mb
ePub File Size: 5.19 Mb
ISBN: 446-6-70716-751-1
Downloads: 77066
Price: Free* [*Free Regsitration Required]
Uploader: Vugal

Use of iron dextran in infants younger than 4 months of age and neonates is not recommended; there have been reports from other countries of an increased incidence of gram-negative sepsis e.

PDR Search

However, trace amounts of unmetabolized iron dextran are excreted in breast milk. Send the page ” ” to a friend, relative, colleague or yourself. Following intramuscular injection of iron dextran, the drug is slowly absorbed in two stages primarily through the lymphatic system. The liver is one of the main storage sites for iron, and advanced chronic liver disease may result in excess storage iron in the liver.

Infants 4 months prescribinng older weighing less than 5 kg.

Iron dextran (INFeD)

It would be illogical for a patient to receive both iron supplementation and deferasirox simultaneously. If test dose uneventful, doses of 1.

If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.

A test dose should be administered before the administration of the therapeutic dose. There is some concern that intravenously administered iron is not used appropriately by the body.

Patients who require parenteral nutrition for a limited period of time and who are not iron-deficient do not need parenteral iron supplementation. Iron dextran is administered intramuscularly or intravenously. Iron dextran should only be used in patients with a clear and confirmed need for parenteral iron therapy. Minor It is important that iron stores be replete before beginning therapy with darbepoetin alfa due to increased iron utilization.

  ALLPLAN MANUALE PDF

Therefore, the therapeutic prescription use of iron is usually compatible with breast-feeding if the lactating mother needs treatment for iron deficiency.

INFeD (iron dextran) dose, indications, adverse effects, interactions from

Adult men, Adolescent males, and Postmenopausal women. Fatal anaphylactoid reactions have occurred during the parenteral administration of iron dextran. Iron dextran is classified in FDA pregnancy risk category C.

Both animal and human data indicate that the bulk of intravenous iron is sequestered in the reticuloendothelial system i. Inadequate iron stores will interfere with the therapeutic response to these agents e. Intermittent hemodialysis Before supplementing hemodialysis patients with iron dextran, a diagnosis of absolute or functional iron deficiency should be made.

Iron dextran (INFeD) | – A Hematology Oncology Wiki

Facilities for cardiopulmonary resuscitation and personnel trained in the detection and treatment of anaphylactoid reactions must be available during administration. Fatal reactions have occurred following the test dose of iron dextran and also have occurred after other prescrkbing when the test dose was tolerated.

Once the infusion is completed, flush vein with NS injection. Deferoxamine is indicated infformation a treatment of iron toxicity or overdose. There is no destructive metabolism of iron because it takes place in a closed system. Total dosage with iron dextran must be individualized according to the patients age, weight, and the degree of the iron-deficiency anemia. A test dose should be given prior to administration of the initial therapeutic dose.

Monitor patients for signs innformation symptoms of anaphylactoid reactions during all iron dextran administrations.

Your email has been sent. A therapeutic response to treatment with iron products is dependent on the patient’s ability to absorb and use the iron, and it is influenced by the cause of the deficiency as well as other illnesses that can affect normal erythropoiesis.

  GUIA AUTOMETRICA 2013 PDF

Since the anemia may be a result of a systemic disturbance, such as recurrent blood prescribong, the underlying cause s should be corrected, if possible. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.

Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. informafion

Infants and Children 4 months and older weighing less than 15 kg. Oral iron supplementation should be discontinued before parenteral administration of iron.

Because anaphylactic reactions are known to occur after uneventful test doses, subsequent test doses should be considered. Major Parenteral iron formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory.

These dimercaprol-iron complexes are more toxic than the metal alone, especially to the kidneys. If test dose uneventful, give the remainder of the total dose as 50 mg of iron dextran per day IM or slow IV until the total calculated dose is given. There are limits to the volume of iron dextran that may be injected IV undiluted per 24 hours based on patient age and weight; see dosage guidelines.

Give DexFerrum test doses gradually over at least 5 minutes. Administer supplemental iron therapy when serum ferritin is Fosinopril: Iron dextran is contraindicated for use in patients with anemia not associated with iron deficiency.

Anemia, hemochromatosis, hemoglobinopathy, hemosiderosis. Do not administer iron dextran to patients with evidence of iron overload e.